PL1951283T3 - Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika - Google Patents

Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika

Info

Publication number
PL1951283T3
PL1951283T3 PL06812748T PL06812748T PL1951283T3 PL 1951283 T3 PL1951283 T3 PL 1951283T3 PL 06812748 T PL06812748 T PL 06812748T PL 06812748 T PL06812748 T PL 06812748T PL 1951283 T3 PL1951283 T3 PL 1951283T3
Authority
PL
Poland
Prior art keywords
ovarian cancer
treating
pharmaceutical composition
glycoproteins
polypeptides
Prior art date
Application number
PL06812748T
Other languages
English (en)
Inventor
Bennink Herman Jan Tijmen Coelingh
Visser Monique
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Publication of PL1951283T3 publication Critical patent/PL1951283T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06812748T 2005-11-16 2006-11-16 Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika PL1951283T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73687705P 2005-11-16 2005-11-16
EP05110819 2005-11-16
EP06812748A EP1951283B1 (en) 2005-11-16 2006-11-16 Pharmaceutical composition for treating or preventing ovarian cancer
PCT/NL2006/050289 WO2007058536A1 (en) 2005-11-16 2006-11-16 Pharmaceutical composition for treating or preventing ovarian cancer

Publications (1)

Publication Number Publication Date
PL1951283T3 true PL1951283T3 (pl) 2010-12-31

Family

ID=37686152

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06812748T PL1951283T3 (pl) 2005-11-16 2006-11-16 Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika

Country Status (8)

Country Link
US (1) US7968514B2 (pl)
EP (1) EP1951283B1 (pl)
CN (1) CN101365473B (pl)
AT (1) ATE473756T1 (pl)
CA (1) CA2630175C (pl)
DE (1) DE602006015508D1 (pl)
PL (1) PL1951283T3 (pl)
WO (1) WO2007058536A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012026820A2 (en) * 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
IN2014CN02496A (pl) * 2011-09-15 2015-06-19 Univ Southern California
CN104804075A (zh) * 2014-01-24 2015-07-29 中南大学 变异的人卵透明带蛋白1和突变基因及检测方法和应用
MX2016013027A (es) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
WO2020048924A1 (en) 2018-09-03 2020-03-12 Laboratoire Hra-Pharma Zp3 fragments in immunotherapy of ovarian cancer
WO2023066923A1 (en) 2021-10-19 2023-04-27 Rahman Nafis Male contraception

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641487A (en) * 1989-06-12 1997-06-24 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides
JPH0799974A (ja) * 1993-10-05 1995-04-18 Tonen Corp ヒト卵透明帯−２蛋白質をコードするｄｎａ
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
EP1056858B1 (en) * 1998-02-19 2004-12-08 Eastern Virginia Medical School RECOMBINANT ACTIVE HUMAN ZONA PELLUCIDA PROTEIN 3 (hZP3)
US6455041B1 (en) * 1998-11-17 2002-09-24 Bonita S. Dunbar Immunogenic epitopes of the human zona pellucida protein (ZP1)
CA2378472A1 (en) * 1999-07-01 2001-01-11 The University Of Georgia Research Foundation, Inc. Method and composition for affecting reproductive systems
US6455941B1 (en) 2001-01-03 2002-09-24 Advanced Semiconductor Engineering, Inc. Chip scale package
EP2050827A3 (en) * 2003-09-18 2009-09-02 Genmab A/S Differentially Expressed Tumour-specific Polypeptides for use in the Diagnosis and Treatment of Cancer

Also Published As

Publication number Publication date
WO2007058536A1 (en) 2007-05-24
CN101365473A (zh) 2009-02-11
CA2630175A1 (en) 2007-05-24
DE602006015508D1 (de) 2010-08-26
EP1951283A1 (en) 2008-08-06
CA2630175C (en) 2018-10-23
ATE473756T1 (de) 2010-07-15
US7968514B2 (en) 2011-06-28
CN101365473B (zh) 2013-04-03
EP1951283B1 (en) 2010-07-14
US20090060931A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
PL1951283T3 (pl) Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika
WO2006081826A3 (en) Survivin peptide vaccine
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CR20220136A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
MX2020010701A (es) Péptidos antigénicos para la prevención y el tratamiento del cáncer.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
WO2006023598A3 (en) Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
MX355054B (es) Péptido de epítope hig2 y urlc10 y vacunas que contienen el mismo.
PH12021551372A1 (en) Human alpha-galactosidase variants
PT1290160E (pt) Polipeptideos pellino humanos
WO2012026820A3 (en) Immunotherapeutic method for treating prostate cancer
WO2004053092A3 (en) Human pellino polypeptides
MX2019012083A (es) Nueva vacuna de peptidos contra la pcsk9.
WO2016080830A3 (en) Immunotherapeutic method for treating pancreatic cancer
WO2004031354A3 (en) Human sarcoma-associated antigens
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen